The recently published randomized controlled Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study evaluated the effect of nateglinide in people with impaired glucose tolerance (IGT) who also had cardiovascular disease (CVD) or CVD risk factors (1). After a median of five years, there was no effect on either incident diabetes or CVD. In five studies (2,,,6) in which the development of diabetes in subjects with IGT was delayed by lifestyle intervention or drugs, the beneficial effect was postulated to be mainly due to decreasing insulin resistance with resulting less demands on β-cell insulin secretion. On the other hand, subjects with IGT in an older small study treated with tolbutamide (a first-generation sulfonylurea agent) (7) or in the more recent Study To Prevent Noninsulin-Dependent Diabetes Mellitus (STOP-NIDDM) given acarbose (8), there was significantly less incident diabetes than in their control groups. (The STOP-NIDDM study, however, has been severely criticized [9]). Neither tolbutamide nor acarbose are thought to primarily affect insulin resistance. It is very possible, of course, that all of these drugs were simply masking the development of diabetes by treating hyperglycemia (10). If so, nateglinide was unable to accomplish this.

The rationale for the CVD end point in the NAVIGATOR study might have been that glucose levels after a glucose challenge, extending all the way down into the midnormal range, are associated with CVD (11). It is important to point out that in many articles postprandial glucose is used mistakenly to describe glucose levels after the nonphysiologic large amount of glucose ingested for the oral glucose tolerance test. In the only study I could find in which CVD events were related to postprandial glucose concentrations, i.e., after meals, these levels were more predictive than fasting plasma glucose (FPG) concentrations in a bivariate analysis (12). In a multivariate analysis, only the value after lunch remained significant. Since nateglinide has a more profound effect on postprandial glucose concentrations than on fasting ones in people with diabetes, it was chosen to test the hypothesis that lowering postprandial glucose levels might have a beneficial effect on people at risk for CVD and the development of diabetes. That it did not might not be too surprising because day-to-day glucose levels in people with IGT on weight maintaining diets (35 kcal/kg) were not increased (13,15). On the other hand, the perhaps problematic STOP-NIDDM study showed that acarbose was associated with decreased incidents of CVD and hypertension (16).

However, in contrast with people with IGT, postprandial glucose concentrations are certainly increased in diabetic patients. There is much speculation that specifically targeting these levels might be beneficial for both the microvascular and macrovascular complications of diabetes (17). Brownlee (18) laid out an intricate theoretical framework of how postprandial hyperglycemia might cause the whole gamut of diabetic complications. This involves increasing glucose concentrations causing oxidative stress reflected in altered mitochondrial function, which causes inhibition of glyceraldehyde phosphate dehydrogenase. This, in turn, leads to increased activity of four biochemical pathways associated with the complications of diabetes, i.e., the polyol, hexosamine, protein kinase C, and advanced glycation end product pathways. Could this be the mechanism whereby the rise in postprandial glucose concentrations leads to diabetic complications? Let's examine the evidence for this intriguing hypothesis.

In vitro incubations of various tissues and cell lines with increasing concentrations of glucose lead to products that reflect oxidative stress (19). One study (20) did show that mitochondrial function in biopsies from the muscle of diabetic subjects was impaired while three other studies (21,23) could not confirm this finding.

Increased variability of daily glycemia is often taken as a surrogate measure for higher postprandial glucose excursions (24). Yet retinopathy was unrelated to this variability, although it remained related to mean glycemia (25). Urinary excretion of free 8-iso-PGF is postulated to reflect oxidative stress, and its excretion is inhibited by vitamin E, an antioxidant (26). One study did find that glucose variability, measured by the mean amplitude of glycemic excursions, was positively correlated with urinary free 8-iso-PGF (27), but this could not be confirmed in two other studies (28,29). Rather, urinary free 8-iso-PGF levels were increased in diabetic patients and lowered by improved diabetic control (26).

Endothelial dysfunction is an early manifestation of atherosclerosis (30). Endothelial function, measured by flow-mediated dilation, decreased in people with diabetes after eating in association with rising postprandial glucose levels but did not change in healthy subjects who have much less of a postprandial rise (31). Artificially raising glucose concentrations with intravenous glucose also decreased flow-mediated dilation and increased oxidative stress, as reflected in increased plasma nitrotyrosine, in both healthy subjects and type 2 diabetic patients (32). Both of these responses to intravenous glucose were blocked by an infusion of vitamin C, also an antioxidant, in healthy subjects but not in those with diabetes (33).

Carotid artery intima-medial thickening (CIMT) reflects coronary artery disease (34). In a cross-sectional study, CIMT correlated with the postprandial rise in glucose concentrations (35). In a prospective study, CIMT did not change in patients treated for three years with voglibose, an α-glucosidase inhibitor, compared with a 0.1 mm increase in those given a placebo with a significant difference between the two groups (36). In another prospective study in drug-naïve patients, there was a small but significant 0.03 mm decrease in CIMT over 1 year in a large number of patients treated with replaginide but no change in those treated with glyburide (37).

In terms of clinical events, a meta-analysis evaluated seven randomized, placebo-controlled acarbose studies carried out between 1987 and 1999. The primary outcome measure was the time to develop a CVD event. There was a significant 2% reduction over a 2-year period in the percent of type 2 diabetic patients treated with acarbose who suffered a CVD event (38). These patients also had significant reductions in A1C and FPG levels as well as postprandial glucose levels. On the other hand, documented significant lowering of postprandial glucose levels in the recent Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) study by premeal lispro insulin in diabetic patients with a recent acute myocardial infarction did not decrease the recurrence of a CVD event compared with basal NPH or glargine insulin, which significantly lowered FPG concentrations (39). There was no difference in A1C levels between the two groups during this study.

How do these data serve to influence our clinical approach to postprandial hyperglycemia? The most important determinant of the postprandial glucose concentration is the preprandial level. Furthermore, the increment over the preprandial level is similar regardless of the preprandial value (40,42). Therefore, postprandial hyperglycemia is best treated by lowering preprandial glycemia. Since randomized controlled intervention studies have clearly demonstrated that keeping A1C levels below 7.0% is beneficial for the microvascular complications of diabetes (43,45) (although perhaps not for the macrovascular ones [46,48]), that should be our primary goal. Once preprandial glucose targets are attained and if A1C levels are ≥7.0%, then and only then would specifically targeting postprandial glycemia be appropriate. If preprandial glucose values are reached and A1C levels are <7.0%, current clinical evidence is not strong enough to expose these patients to the increased risk of hypoglycemia by aggressively targeting postprandial glycemia.

No potential conflicts of interest relevant to this article were reported.

1.
NAVIGATOR Study Group
McMurray
JJ
,
Holman
RR
,
Haffner
SM
,
Bethel
MA
,
Holzhauer
B
,
Hua
TA
,
Belenkov
Y
,
Boolell
M
,
Buse
JB
,
Buckley
BM
,
Chacra
AR
,
Chiang
FT
,
Charbonnel
B
,
Chow
CC
,
Davies
MJ
,
Deedwania
P
,
Diem
P
,
Einhorn
D
,
Fonseca
V
,
Fulcher
GR
,
Gaciong
Z
,
Gaztambide
S
,
Giles
T
,
Horton
E
,
Ilkova
H
,
Jenssen
T
,
Kahn
SE
,
Krum
H
,
Laakso
M
,
Leiter
LA
,
Levitt
NS
,
Mareev
V
,
Martinez
F
,
Masson
C
,
Mazzone
T
,
Meaney
E
,
Nesto
R
,
Pan
C
,
Prager
R
,
Raptis
SA
,
Rutten
GE
,
Sandstroem
H
,
Schaper
F
,
Scheen
A
,
Schmitz
O
,
Sinay
I
,
Soska
V
,
Stender
S
,
Tamás
G
,
Tognoni
G
,
Tuomilehto
J
,
Villamil
AS
,
Vozár
J
,
Califf
RM
:
Effect of nateglinide on the incidence of diabetes and cardiovascular events
.
N Engl J Med
2010
;
362
:
1477
1490
2.
Tuomilehto
J
,
Lindström
J
,
Eriksson
JG
,
Valle
TT
,
Hämäläinen
H
,
Ilanne-Parikka
P
,
Keinänen-Kiukaanniemi
S
,
Laakso
M
,
Louheranta
A
,
Rastas
M
,
Salminen
V
,
Uusitupa
M
:
Finnish Diabetes Prevention Study Group
.
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
.
N Engl J Med
2001
;
344
:
1343
1350
3.
Knowler
WC
,
Barrett-Connor
E
,
Fowler
SE
,
Hamman
RF
,
Lachin
JM
,
Walker
EA
,
Nathan
DM
:
Diabetes Prevention Program Research Group
.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
.
N Engl J Med
2002
;
346
:
393
403
4.
Knowler
WC
,
Hamman
RF
,
Edelstein
SL
,
Barrett-Connor
E
,
Ehrmann
DA
,
Walker
EA
,
Fowler
SE
,
Nathan
DM
,
Kahn
SE
:
Diabetes Prevention Program Research Group
.
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program
.
Diabetes
2005
;
54
:
1150
1156
5.
Ramachandran
A
,
Snehalatha
C
,
Mary
S
,
Mukesh
B
,
Bhaskar
AD
,
Vijay
V
:
Indian Diabetes Prevention Programme (IDPP)
.
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)
.
Diabetologia
2006
;
49
:
289
297
6.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
Gerstein
HC
,
Yusuf
S
,
Bosch
J
,
Pogue
J
,
Sheridan
P
,
Dinccag
N
,
Hanefeld
M
,
Hoogwerf
B
,
Laakso
M
,
Mohan
V
,
Shaw
J
,
Zinman
B
,
Holman
RR
:
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
.
Lancet
2006
;
368
:
1096
1105
7.
Sartor
G
,
Scherstén
B
,
Carlström
S
,
Melander
A
,
Nordén
A
,
Persson
G
:
Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation
.
Diabetes
1980
;
29
:
41
49
8.
Chiasson
JL
,
Josse
RG
,
Gomis
R
,
Hanefeld
M
,
Karasik
A
,
Laakso
M
:
STOP-NIDDM Trail Research Group
.
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
.
Lancet
2002
;
359
:
2072
2077
9.
Kaiser
T
,
Sawicki
PT
:
STOP-IDDM Trial Research Group
.
Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data
.
Diabetologia
2004
;
47
:
575
580
10.
Buchanan
TA
:
(How) can we prevent type 2 diabetes?
Diabetes
2007
;
56
:
1502
1507
11.
Bonora
E
,
Muggeo
M
:
Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence
.
Diabetologia
2001
;
44
:
2107
2114
12.
Cavalot
F
,
Petrelli
A
,
Traversa
M
,
Bonomo
K
,
Fiora
E
,
Conti
M
,
Anfossi
G
,
Costa
G
,
Trovati
M
:
Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study
.
J Clin Endocrinol Metab
2006
;
91
:
813
819
13.
Reaven
GM
,
Olefsky
J
,
Farquhar
JW
:
Does hyperglycaemia or hyperinsulinaemia characterize the patient with chemical diabetes?
Lancet
1972
;
1
:
1247
1249
14.
Golay
A
,
Chen
YD
,
Reaven
GM
:
Effect of differences in glucose tolerance on insulin's ability to regulate carbohydrate and free fatty acid metabolism in obese individuals
.
J Clin Endocrinol Metab
1986
;
62
:
1081
1088
15.
Reaven
GM
,
Chen
Y-DI
,
Hollenbeck
CB
,
Sheu
WHH
,
Ostrega
D
,
Polonsky
KS
:
Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance
J Clin Endocrinol Metab
1993
;
76
:
44
48
16.
Chiasson
JL
,
Josse
RG
,
Gomis
R
,
Hanefeld
M
,
Karasik
A
,
Laakso
M
:
STOP-NIDDM Trial Research Group
.
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance; the STOP-NIDDM trial
.
JAMA
2003
;
290
:
486
494
17.
Ceriello
A
,
Hanefeld
M
,
Leiter
L
,
Monnier
L
,
Moses
A
,
Owens
D
,
Tajima
N
,
Tuomilehto
J
:
Postprandial glucose regulation and diabetic complications
.
Arch Intern Med
2004
;
164
:
2090
2095
18.
Brownlee
M
:
The pathobiology of diabetic complications: a unifying mechanism
.
Diabetes
2005
;
54
:
1615
1625
19.
Hirsch
IB
,
Brownlee
M
:
Should minimal blood glucose variability become the gold standard of glycemic control?
J Diabetes Complications
2005
;
19
:
178
181
20.
Mogensen
M
,
Sahlin
K
,
Fernström
M
,
Glintborg
D
,
Vind
BF
,
Beck-Nielsen
H
,
Højlund
K
:
Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes
.
Diabetes
2007
;
56
:
1592
1599
21.
Boushel
R
,
Gnaiger
E
,
Schjerling
P
,
Skovbro
M
,
Kraunsøe
R
,
Dela
F
:
Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle
.
Diabetologia
2007
;
50
:
790
796
22.
Rabøl
R
,
Højberg
PM
,
Almdal
T
,
Boushel
R
,
Haugaard
SB
,
Madsbad
S
,
Dela
F
:
Effect of hyperglycemia on mitochondrial respiration in type 2 diabetes
.
J Clin Endocrinol Metab
2009
;
94
:
1372
1378
23.
Abdul-Ghani
MA
,
Jani
R
,
Chavez
A
,
Molina-Carrion
M
,
Tripathy
D
,
DeFronzo
RA
:
Mitochondrial reactive oxygen species generation in obese non-diabetic and type 2 diabetic participants
.
Diabetologia
2009
;
52
:
574
582
24.
Weber
C
,
Schnell
O
:
The assessment of glycemic variability and its impact on diabetes-related complications: an overview
.
Diabetes Technol Ther
2009
;
11
:
623
633
25.
Kilpatrick
ES
,
Rigby
AS
,
Atkin
SL
:
The effect of glucose variability on the risk of microvascular complications in type 1 diabetes
.
Diabetes Care
2006
;
29
:
1486
1490
26.
Davì
G
,
Ciabattoni
G
,
Consoli
A
,
Mezzetti
A
,
Falco
A
,
Santarone
S
,
Pennese
E
,
Vitacolonna
E
,
Bucciarelli
T
,
Costantini
F
,
Capani
F
,
Patrono
C
:
In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation
.
Circulation
1999
;
99
:
224
229
27.
Monnier
L
,
Mas
E
,
Ginet
C
,
Michel
F
,
Villon
L
,
Cristol
JP
,
Colette
C
:
Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes
.
JAMA
2006
;
295
:
1681
1687
28.
Wentholt
IM
,
Kulik
W
,
Michels
RP
,
Hoekstra
JB
,
DeVries
JH
:
Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes
.
Diabetologia
2008
;
51
:
183
190
29.
Siegelaar
SE
,
Kulik
W
,
van Lenthe
H
,
Mukherjee
R
,
Hoekstra
JB
,
Devries
JH
:
A randomized clinical trial comparing the effect of basal insulin and inhaled mealtime insulin on glucose variability and oxidative stress
.
Diabetes Obes Metab
2009
;
11
:
709
714
30.
Grover-Páez
F
,
Zavalza-Gómez
AB
:
Endothelial dysfunction and cardiovascular risk factors
.
Diabetes Res Clin Pract
2009
;
84
:
1
10
31.
Ceriello
A
,
Cavarape
A
,
Martinelli
L
,
Da Ros
R
,
Marra
G
,
Quagliaro
L
,
Piconi
L
,
Assaloni
R
,
Motz
E
:
The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart
.
Diabet Med
2004
;
21
:
171
175
32.
Ceriello
A
,
Esposito
K
,
Piconi
L
,
Ihnat
M
,
Thorpe
J
,
Testa
R
,
Bonfigli
AR
,
Giugliano
D
:
Glucose “peak” and glucose “spike”: impact on endothelial function and oxidative stress
.
Diabetes Res Clin Pract
2008
;
82
:
262
267
33.
Ceriello
A
,
Esposito
K
,
Piconi
L
,
Ihnat
MA
,
Thorpe
JE
,
Testa
R
,
Boemi
M
,
Giugliano
D
:
Oscillating glucose is more deleterious to endotherial function and oxidative stress than mean glucose in normal and type 2 diabetic patients
.
Diabetes
2008
;
57
:
1349
1354
34.
O'Leary
DH
,
Polak
JF
,
Kronmal
RA
,
Manolio
TA
,
Burke
GL
,
Wolfson
SK
 Jr
:
Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group
.
N Engl J Med
1999
;
340
:
14
22
35.
Esposito
K
,
Ciotola
M
,
Carleo
D
,
Schisano
B
,
Sardelli
L
,
Di Tommaso
D
,
Misso
L
,
Saccomanno
F
,
Ceriello
A
,
Giugliano
D
:
Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes
.
J Clin Endocrinol Metab
2008
;
93
:
1345
1350
36.
Yamasaki
Y
,
Katakami
N
,
Hayaishi-Okano
R
,
Matsuhisa
M
,
Kajimoto
Y
,
Kosugi
K
,
Hatano
M
,
Hori
M
:
alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness
.
Diabetes Res Clin Pract
2005
;
67
:
204
210
37.
Esposito
K
,
Giugliano
D
,
Nappo
F
,
Marfella
R
:
Campanian Postprandial Hyperglycemia Study Group
.
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes
.
Circulation
2004
;
110
:
214
219
38.
Hanefeld
M
,
Cagatay
M
,
Petrowitsch
T
,
Neuser
D
,
Petzinna
D
,
Rupp
M
:
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
.
Eur Heart J
2004
;
25
:
10
16
39.
Raz
I
,
Wilson
PW
,
Strojek
K
,
Kowalska
I
,
Bozikov
V
,
Gitt
AK
,
Jermendy
G
,
Campaigne
BN
,
Kerr
L
,
Milicevic
Z
,
Jacober
SJ
:
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial
.
Diabetes Care
2009
;
32
:
381
386
40.
Cusi
K
,
Cunningham
GR
,
Comstock
JP
:
Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM
.
Diabetes Care
1995
;
18
:
843
851
41.
Monnier
L
,
Colette
C
,
Dunseath
GJ
,
Owens
DR
:
The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes
.
Diabetes Care
2007
;
30
:
263
269
42.
Bonomo
K
,
De Salve
A
,
Fiora
E
,
Mularoni
E
,
Massucco
P
,
Poy
P
,
Pomero
A
,
Cavalot
F
,
Anfossi
G
,
Trovati
M
:
Evaluation of a simple policy for pre- and post-prandial blood glucose self-monitoring in people with type 2 diabetes not on insulin
.
Diabetes Res Clin Pract
2010
;
87
:
246
251
43.
The Diabetes Control and Complications Trial Research Group
.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-independent diabetes mellitus
.
N Engl J Med
1993
;
329
:
977
986
44.
Ohkubo
Y
,
Kishikawa
H
,
Araki
E
,
Miyata
T
,
Isami
S
,
Motoyoshi
S
,
Kojima
Y
,
Furuyoshi
N
,
Shichiri
M
:
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study
.
Diabetes Res Clin Pract
1995
;
28
:
103
117
45.
UK Prospective Diabetes Study (UKPDS) Group
.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
.
Lancet
1998
;
352
:
837
853
46.
Action to Control Cardiovascular Risk in Diabetes Study Group
Gerstein
HC
,
Miller
ME
,
Byington
RP
,
Goff
DC
 Jr
,
Bigger
JT
,
Buse
JB
,
Cushman
WC
,
Genuth
S
,
Ismail-Beigi
F
,
Grimm
RH
 Jr
,
Probstfield
JL
,
Simons-Morton
DG
,
Friedewald
WT
:
Effects of intensive glucose lowering in type 2 diabetes
.
N Engl J Med
2008
;
358
:
2545
2559
47.
ADVANCE Collaborative Group
Patel
A
,
MacMahon
S
,
Chalmers
J
,
Neal
B
,
Billot
L
,
Woodward
M
,
Marre
M
,
Cooper
M
,
Glasziou
P
,
Grobbee
D
,
Hamet
P
,
Harrap
S
,
Heller
S
,
Liu
L
,
Mancia
G
,
Mogensen
CE
,
Pan
C
,
Poulter
N
,
Rodgers
A
,
Williams
B
,
Bompoint
S
,
de Galan
BE
,
Joshi
R
,
Travert
F
:
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
.
N Engl J Med
2008
;
358
:
2560
2572
48.
Duckworth
W
,
Abraira
C
,
Moritz
T
,
Reda
D
,
Emanuele
N
,
Reaven
PD
,
Zieve
FJ
,
Marks
J
,
Davis
SN
,
Hayward
R
,
Warren
SR
,
Goldman
S
,
McCarren
M
,
Vitek
ME
,
Henderson
WG
,
Huang
GD
:
VADT Investigators
.
Glucose control and vascular complications in veterans with type 2 diabetes
.
N Engl J Med
2009
;
360
:
129
139
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.